Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18792783 | 0.98 | KDM4E (0.39) | KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL8063331 | 0.98 | KDM4E (0.39) | KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL1368658 | 0.87 | KDM4E (0.42) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL22932152 | 0.86 | ALDH1A1 (0.34) | KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL9541679 | 0.85 | KDM4E (0.45) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL14198320 | 0.85 | KDM4E (0.45) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL9540608 | 0.85 | KDM4E (0.45) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL19606314 | 0.85 | KDM4E (0.33) | KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL22851377 | 0.85 | POLB (0.38) | KDM4EALDH1A1 | |
| SCHEMBL24246012 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180222847-A1 | DIAMINE HAVING TERT-ALKYLAMINO GROUP AND PRIMARY AMINO GROUP FOR USE IN GAS SCRUBBING | BASF SE (DE) | 2018-08-09 | — | — | US | claimed |
| EP-3186222-B1 | DIAMINE WITH TERTIARY ALKYL-AMINO AND PRIMARY AMINO GROUP FOR USE IN GAS SCRUBBING | BASF SE (DE) | 2018-06-06 | — | — | EP | claimed |
| EP-3186222-A1 | DIAMINE HAVING TERT-ALKYLAMINO GROUP AND PRIMARY AMINO GROUP FOR USE IN GAS SCRUBBING | BASF SE (DE) | 2017-07-05 | — | — | EP | claimed |
| WO-2016030277-A1 | DIAMINE HAVING TERT-ALKYLAMINO GROUP AND PRIMARY AMINO GROUP FOR USE IN GAS SCRUBBING | BASF SE (DE) | 2016-03-03 | — | — | WO | claimed |
| WO-2023118961-A1 | ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF | INTOCELL, INC. (KR) | 2023-06-29 | — | — | WO | disclosed |
| US-11584748-B2 | Spirocyclic compounds | C4 THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20230019060-A1 | HETEROCYCLIC COMPOUNDS FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-11242323-B2 | Inhibition of OLIG2 activity | Curtana Pharmaceuticals, Inc. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20210253535-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2021-08-19 | — | — | US | disclosed |
| US-20210032245-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2021-02-04 | — | — | US | disclosed |
| CN-106604771-B | Diamines with tertiary alkylamino and primary amino groups for gas scrubbing | 巴斯夫欧洲公司 | 2020-06-09 | — | — | CN | disclosed |
| CN-106604771-B | Diamines with tertiary alkylamino and primary amino groups for gas scrubbing | 巴斯夫欧洲公司 | 2020-06-09 | — | — | CN | disclosed |
| US-20080058636-A1 | METHODS OF MYOCARDIAL IMAGING | EPIX PHARMACEUTICALS, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080044360-A1 | METHODS OF COLLAGEN IMAGING | EPIX PHARMACEUTICALS, INC. | 2008-02-21 | — | — | US | disclosed |
| US-20070293656-A1 | COLLAGEN BINDING PEPTIDES | EPIX PHARMACEUTICALS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-20070185311-A1 | Peptide-Based Multimeric Targeted Contrast Agents | EPIX PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| US-20070154948-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-07-05 | — | — | US | disclosed |
| US-7238341-B2 | Peptide-based multimeric targeted contrast agents | EPIX PHARMACEUTICALS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-20060039861-A1 | Peptide-based multimeric targeted contrast agents | EPIX MEDICAL, INC., A DELAWARE CORPORATION | 2006-02-23 | — | — | US | disclosed |
| US-20050074411-A1 | Peptide-based multimeric targeted contrast agents | EPIX MEDICAL, INC. A DELAWARE CORPORATION | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060039861-A1 | Peptide-based multimeric targeted contrast agents | NGLY1, IAPP, NPPA | KDM4E 4774/4885ALDH1A1 4848/4885GAA 2063/4885 |
| US-20230019060-A1 | HETEROCYCLIC COMPOUNDS FOR MEDICAL TREATMENT | CRBN, MDM2, RBX1 | KDM4E 1086/4885ALDH1A1 2742/4885GAA 1626/4885 |
| US-20210253535-A1 | INHIBITION OF OLIG2 ACTIVITY | GLI2, ING2, GMFG | KDM4E 2547/4885ALDH1A1 1478/4885GAA 2405/4885 |
| US-20180222847-A1 | DIAMINE HAVING TERT-ALKYLAMINO GROUP AND PRIMARY AMINO GROUP FOR USE IN GAS SCRUBBING | TST, ALKBH1, CTH | KDM4E 1030/4885ALDH1A1 583/4885GAA 4767/4885 |
| US-20080058636-A1 | METHODS OF MYOCARDIAL IMAGING | FABP3, TNNI3, TNNT2 | KDM4E 4464/4885ALDH1A1 4515/4885GAA 3486/4885 |
| US-20070185311-A1 | Peptide-Based Multimeric Targeted Contrast Agents | NGLY1, IAPP, NPPA | KDM4E 4774/4885ALDH1A1 4848/4885GAA 2063/4885 |
| US-20080044360-A1 | METHODS OF COLLAGEN IMAGING | COL14A1, COL2A1, COL1A1 | KDM4E 4372/4885ALDH1A1 4592/4885GAA 3768/4885 |
| US-20050074411-A1 | Peptide-based multimeric targeted contrast agents | NGLY1, IAPP, NPPA | KDM4E 4774/4885ALDH1A1 4848/4885GAA 2063/4885 |
| US-20210032245-A1 | SPIROCYCLIC COMPOUNDS | CRBN, RBX1, XIAP | KDM4E 1861/4885ALDH1A1 2000/4885GAA 2719/4885 |
| US-20070293656-A1 | COLLAGEN BINDING PEPTIDES | COL14A1, COL2A1, COL1A1 | KDM4E 4176/4885ALDH1A1 4339/4885GAA 2574/4885 |
| US-11242323-B2 | Inhibition of OLIG2 activity | POU2F2, ING2, PAX2 | KDM4E 2188/4885ALDH1A1 1801/4885GAA 2429/4885 |
| US-11584748-B2 | Spirocyclic compounds | CRBN, RBX1, XIAP | KDM4E 1861/4885ALDH1A1 2000/4885GAA 2719/4885 |
| US-20070154948-A1 | Novel antibacterial agents | ENGASE, PGLS, PEPD | KDM4E 2410/4885ALDH1A1 2244/4885GAA 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.